Krystal Biotech, Inc. (KRYS)
- Previous Close
159.05 - Open
157.92 - Bid 155.11 x 100
- Ask 156.42 x 100
- Day's Range
153.74 - 157.71 - 52 Week Range
82.09 - 189.97 - Volume
236,331 - Avg. Volume
397,530 - Market Cap (intraday)
4.439B - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
399.18 - EPS (TTM)
0.39 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
188.50
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
www.krystalbio.comRecent News: KRYS
Performance Overview: KRYS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRYS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRYS
Valuation Measures
Market Cap
4.44B
Enterprise Value
3.92B
Trailing P/E
399.18
Forward P/E
416.67
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
85.22
Price/Book (mrq)
5.70
Enterprise Value/Revenue
77.22
Enterprise Value/EBITDA
218.67
Financial Highlights
Profitability and Income Statement
Profit Margin
21.56%
Return on Assets (ttm)
-8.83%
Return on Equity (ttm)
1.68%
Revenue (ttm)
50.7M
Net Income Avi to Common (ttm)
10.93M
Diluted EPS (ttm)
0.39
Balance Sheet and Cash Flow
Total Cash (mrq)
532.18M
Total Debt/Equity (mrq)
1.04%
Levered Free Cash Flow (ttm)
-74.41M